Now when we talk about Revenue Estimate for the current Fiscal Quarter, Average Revenue Estimate of Boston Scientific Corporation (BSX) is projected as $2.04 Billion where Low Revenue estimate and High Revenue Estimates are $2.02 Billion and $2.08 Billion respectively by 23 analysts. The company’s Market capitalization is $11.15 Billion with the total Outstanding Shares of 268.83 Million.
Advertisement
Several hedge funds and institutional investors have modified their holdings of the company. With 8.96 million shares average volume, it will take short sellers 2 days to cover their BSX’s short positions. The stock now has Price to Sales (P/S) value of 4 where Price to Book (P/B) value stands at 4.73.BSX is now showing ROA (Return on Assets) value of -0.2% where ROE (Return on Equity) is -0.6%. The stock is now holding above its 50 day moving average of $8.97 and above its 200 day moving average of $21.76. The median 12-month price target of 25 analysts covering the company is $25.00, which suggests the stock could still gain more than 9 percent. The rating firm gave a Buy rating to this stock in a research note on Mar 17, 2016.Sun Trust Rbsn Humphrey analysts issued their verdict on Boston Scientific Corporation (NYSE:BSX) recently. Analysts had expected Boston Scientific Corporation (NYSE:BSX) to report earnings of about $0.24 per share on $1,912.80M in revenue.
Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 27th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.04.
Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 23.37 up so far this year. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. However, 5 analysts recommended “HOLD RATING” for the company. During the same quarter a year ago, the business earned $0.21 EPS. Winslow Capital Management LLC now owns 21,256,566 shares of the company’s stock worth $391,971,000 after buying an additional 1,641,002 shares during the last quarter.
Advertisement
Boston Scientific Corporation develops manufactures and markets medical devices. SunTrust started coverage on Boston Scientific in a report on Thursday, February 25th. They issued a “buy” rating on the stock. Four analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. Boston Scientific now has a consensus rating of “Buy” and an average target price of $22.89.
